BRCA1 & BRCA2 MUTATION DRUG PROFILING PANEL

This assay detects most of the mutations and insertions/deletions in the BRCA gene which is linked to breast cancer. Using the Oncomine Knowledge base, this assay predicts the response of drugs such as PARP inhibitors and helps to tailor the therapy.

  • Test Type:
  • Pre-test Information:
    Duly filled BRCA 1 & BRCA 2 informed consent form (Form 24) is mandatory.
  • Report Delivery:
    Sample Mon by 9 am; Report 15 days
  • Components:
    0